Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Impact of Smoking Status on the Efficacy of EGFR-TKI Plus Angiogenesis Inhibitor Combination Therapy in Advanced NSCLC
- Effect of Smoking Habits on the Efficacy of EGFR TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
- Addition of Bevacizumab to Erlotinib as First-Line Treatment for EGFR-Mutated Advanced Nonsquamous NSCLC
Disclosure statements are available on the authors' profiles:
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerJAMA Netw Open 2022 May 02;5(5)e2214046, S Popat, SV Liu, N Scheuer, A Gupta, GG Hsu, SV Ramagopalan, F Griesinger, V Subbiah
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.